After RBC Capital surveyed 91 U.S. and EU oncologists, RBC analyst Simos Simeonidis says that the respondents appeared to be "fairly positive" on the potential of Incyte's epacadostat+pembrolizumab combination as a melanoma treatment. The analyst adds that the respondents "would use the regimen widely" if previous positive data on the treatment is replicated in Phase III. About 50% of the doctors would use the treatment even if its median progressive free survival rate is lower than the standard of care, given the superior safety data of Incyte's drug , the analyst noted. RBC keeps a $113 price target and Outperform rating on Incyte.